News | April 14, 2024
Briefs: Sun Pharma and Kimia Biosciences
Sun Pharma's Dadra facility receives OAI status from US FDA
Sun Pharma's Dadra facility receives OAI status from US FDA
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
_256_384.png){kind=logo}
4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months
The registered capital of the newly founded company is € 50 million
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
Subscribe To Our Newsletter & Stay Updated
